Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2023; 11(19): 4648-4654
Published online Jul 6, 2023. doi: 10.12998/wjcc.v11.i19.4648
Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients: Three case reports
Liu Yang, Xin Xu, Liang Wang, Ke-Bin Zeng, Xue-Feng Wang
Liu Yang, Department of Neurology, Central Hospital Affiliated to Chongqing University, Chongqing 400010, China
Xin Xu, Liang Wang, Ke-Bin Zeng, Xue-Feng Wang, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
Author contributions: Xu X and Wang XF were responsible for the neurological diagnosis and treatment; Yang L, Wang L, and Zeng KB were major contributors to the writing of the manuscript; All authors have read and approved the final version of the manuscript; Yang L and Xu X are co-authors, they equally contributed to the work.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xue-Feng Wang, PhD, Professor, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Jiankang Road, Yuzhong District, Chongqing 400010, China. wangxfyp@vip.163.com
Received: January 21, 2023
Peer-review started: January 21, 2023
First decision: March 10, 2023
Revised: March 24, 2023
Accepted: June 13, 2023
Article in press: June 13, 2023
Published online: July 6, 2023
Processing time: 160 Days and 8 Hours
Core Tip

Core Tip: We report three patients with acute cerebral infarction who died after edaravone treatment. Edaravone is used to scavenge oxygen free radicals in patients with acute ischemic stroke, and most clinicians are only aware of its damage to kidney function. However, the main symptoms in patients treated with intravenous edaravone, such as rapid disease change, coagulation dysfunction, cardiac arrest and other side effects are rarely reported. The purpose of this paper is to share the experience of edaravone therapy in clinical practice.